Industry
Johnson & Johnson agrees to acquire Ollin Biosciences
The acquisition gives J&J OLN324, an investigational phase 3 drug being developed for wet age-related macular degeneration and diabetic macular edema.
Johnson & Johnson has agreed to acquire Ollin Biosciences, adding OLN324, an investigational bispecific antibody, to its pipeline. Healio reported that the phase 3 drug is being developed for wet age-related macular degeneration and diabetic macular edema. It targets VEGF and angiopoietin-2. BioPharma Dive reported that early study results supported the drug’s potential, while noting it would enter a crowded market.
Healio said J&J will pay $2.2 billion upfront, with an additional $1.125 billion in potential regulatory and commercial milestone payments. MedCity News described a $1.2 billion upfront payment and up to $1.1 billion in additional payments. Healio said the deal is expected to close before the end of the year. In a separate development funding agreement, Healio reported Blackstone Life Sciences will pay $750 million to J&J, while MedCity News said Blackstone agreed to pay up to $750 million.


